Delcath Systems (DCTH) 1.36 $DCTH
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), CLDX: 17.08 (-0.18), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), PVCT: 0.85 (-0.02), VICL: 1.03 (+0.02), AZN: 70.44 (+0.26), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)
DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS
Thomson Reuters ONE - Mon Dec 15, 6:01AM CST
Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise
DCTH: 1.36 (+0.01)
Delcath Systems adds Hannover Medical School Hospital and Jena University Hospital to its Global Phase 2 HCC Programme
M2 - Fri Dec 12, 7:01AM CST
Medical device company Delcath Systems (NasdaqCM
CTH) disclosed on Thursday the addition of two research hospitals in Germany to its Global Phase 2 Clinical Programme for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC), or primary liver cancer.
DCTH: 1.36 (+0.01)
DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM
Thomson Reuters ONE - Thu Dec 11, 6:01AM CST
Hannover Medical School Hospital and Jena University Hospital in Germany Open for Enrollment
DCTH: 1.36 (+0.01)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.41 (+0.13), AMGN: 160.67 (+3.15), RGLS: 14.78 (+0.24), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), PVCT: 0.85 (-0.02), CANF: 3.70 (+0.01), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80)
DELCATH ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE 2 TRIAL OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER
Thomson Reuters ONE - Mon Nov 10, 5:31AM CST
Goethe University Hospital Frankfurt Performs First Treatment
DCTH: 1.36 (+0.01)
Delcath's (DCTH) CEO Dr. Jennifer Simpson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:58PM CST
DCTH: 1.36 (+0.01)
Delcath Systems (DCTH) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
DCTH: 1.36 (+0.01)
Delcath Systems Q3 EPS of -$0.48
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:09PM CST
DCTH: 1.36 (+0.01)
Delcath Reports 2014 Third Quarter Results
PR Newswire - Wed Nov 05, 3:01PM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results for the fiscal third quarter ended September 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
DCTH: 1.36 (+0.01)
DELCATH TO REPORT THIRD QUARTER 2014 RESULTS ON NOVEMBER 5, 2014
Thomson Reuters ONE - Wed Oct 29, 3:05PM CDT
New York, NY- October 29, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, November 5, 2014 at 4:30 p.m. ET to discuss its financial results for the third quarter of 2014 ended September 30, 2014, and provide an update on recent corporate progress.
DCTH: 1.36 (+0.01)
LEADING CANCER CENTERS TO PRESENT DATA FROM DELCATH'S CHEMOSAT/MELPHALAN HDS AT ESSO CONGRESS
Thomson Reuters ONE - Tue Oct 28, 6:00AM CDT
New York, NY- October 28, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that data highlighting the potential of the Company's Hepatic CHEMOSAT(R) Delivery System/Melphalan HDS will be presented as part of the scientific program at the upcoming European Society of Surgical Oncology (ESSO) congress. Three abstracts detailing the clinical experiences at three leading cancer hospitals using CHEMOSAT/Melphalan HDS to perform percutaneous hepatic perfusion (PHP) will be presented:
DCTH: 1.36 (+0.01)
OTC Daily Alert Stock Watch - Delcath Systems, Inc. (NASDAQ: DCTH)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DCTH: 1.36 (+0.01)
PDI, Inc. Announces Appointment of Graham G. Miao, MBA, Ph.D. as Chief Financial Officer
PR Newswire - Tue Oct 14, 4:31PM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the appointment of Graham G. Miao, MBA, Ph.D., as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), responsible for overseeing the company's financial and operational management to help drive its healthcare commercialization services and molecular diagnostics businesses. He will report to Nancy Lurker, PDI's Chief Executive Officer, and begin his new role on October 20, 2014.
PDII: 1.63 (-0.01), DCTH: 1.36 (+0.01)
Delcath Systems to conduct first-line treatment of patients with unresectable hepatocellular carcinoma in Tampa, Florida, USA
M2 - Tue Oct 07, 6:31AM CDT
Medical device company Delcath Systems (NasdaqCM CTH) reported on Monday that it has begun its US clinical development programme for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
DCTH: 1.36 (+0.01)
DELCATH COMMENCES U.S. PHASE 2 STUDY OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER
Thomson Reuters ONE - Thu Oct 02, 6:00AM CDT
Moffitt Cancer Center In Tampa, Florida Opens For Enrollment
DCTH: 1.36 (+0.01)
Jennifer Simpson, PH. D. Appointed Interim President and Interim-CEO of Delcath Systems; Roger G. Stoll, PH.D Named Executive Chairman
Thomson Reuters ONE - Mon Sep 15, 6:00AM CDT
- Company Enhances Clinical Development Program -
DCTH: 1.36 (+0.01)
5 Active Under-$10 Stocks to Buy Now
at The Street - Wed Aug 20, 5:30AM CDT
When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CRNT: 0.98 (+0.02), PXLW: 4.10 (+0.09), ESI: 10.18 (-0.01), ZHNE: 1.85 (+0.03), DCTH: 1.36 (+0.01)
Delcath Reports 2014 Second Quarter Results
PR Newswire - Wed Aug 06, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal second quarter ended June 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
DCTH: 1.36 (+0.01)
DELCATH TO REPORT SECOND QUARTER 2014 RESULTS ON AUGUST 6, 2014
Thomson Reuters ONE - Fri Aug 01, 5:30AM CDT
NEW YORK, NY - August 1, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, August 6, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter of 2014 ended June 30, 2014, and provide an update on recent corporate progress.
DCTH: 1.36 (+0.01)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), CLDX: 17.08 (-0.18), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), PVCT: 0.85 (-0.02), VICL: 1.03 (+0.02), AZN: 70.44 (+0.26), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)
DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS
Thomson Reuters ONE - Mon Dec 15, 6:01AM CST
Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise
DCTH: 1.36 (+0.01)
Delcath Systems adds Hannover Medical School Hospital and Jena University Hospital to its Global Phase 2 HCC Programme
M2 - Fri Dec 12, 7:01AM CST
Medical device company Delcath Systems (NasdaqCM
CTH) disclosed on Thursday the addition of two research hospitals in Germany to its Global Phase 2 Clinical Programme for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC), or primary liver cancer. DCTH: 1.36 (+0.01)
DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM
Thomson Reuters ONE - Thu Dec 11, 6:01AM CST
Hannover Medical School Hospital and Jena University Hospital in Germany Open for Enrollment
DCTH: 1.36 (+0.01)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.41 (+0.13), AMGN: 160.67 (+3.15), RGLS: 14.78 (+0.24), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), PVCT: 0.85 (-0.02), CANF: 3.70 (+0.01), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80)
DELCATH ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE 2 TRIAL OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER
Thomson Reuters ONE - Mon Nov 10, 5:31AM CST
Goethe University Hospital Frankfurt Performs First Treatment
DCTH: 1.36 (+0.01)
Delcath's (DCTH) CEO Dr. Jennifer Simpson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:58PM CST
DCTH: 1.36 (+0.01)
Delcath Systems (DCTH) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
DCTH: 1.36 (+0.01)
Delcath Systems Q3 EPS of -$0.48
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:09PM CST
DCTH: 1.36 (+0.01)
Delcath Reports 2014 Third Quarter Results
PR Newswire - Wed Nov 05, 3:01PM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results for the fiscal third quarter ended September 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
DCTH: 1.36 (+0.01)
DELCATH TO REPORT THIRD QUARTER 2014 RESULTS ON NOVEMBER 5, 2014
Thomson Reuters ONE - Wed Oct 29, 3:05PM CDT
New York, NY- October 29, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, November 5, 2014 at 4:30 p.m. ET to discuss its financial results for the third quarter of 2014 ended September 30, 2014, and provide an update on recent corporate progress.
DCTH: 1.36 (+0.01)
LEADING CANCER CENTERS TO PRESENT DATA FROM DELCATH'S CHEMOSAT/MELPHALAN HDS AT ESSO CONGRESS
Thomson Reuters ONE - Tue Oct 28, 6:00AM CDT
New York, NY- October 28, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that data highlighting the potential of the Company's Hepatic CHEMOSAT(R) Delivery System/Melphalan HDS will be presented as part of the scientific program at the upcoming European Society of Surgical Oncology (ESSO) congress. Three abstracts detailing the clinical experiences at three leading cancer hospitals using CHEMOSAT/Melphalan HDS to perform percutaneous hepatic perfusion (PHP) will be presented:
DCTH: 1.36 (+0.01)
OTC Daily Alert Stock Watch - Delcath Systems, Inc. (NASDAQ: DCTH)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DCTH: 1.36 (+0.01)
PDI, Inc. Announces Appointment of Graham G. Miao, MBA, Ph.D. as Chief Financial Officer
PR Newswire - Tue Oct 14, 4:31PM CDT
PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the appointment of Graham G. Miao, MBA, Ph.D., as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), responsible for overseeing the company's financial and operational management to help drive its healthcare commercialization services and molecular diagnostics businesses. He will report to Nancy Lurker, PDI's Chief Executive Officer, and begin his new role on October 20, 2014.
PDII: 1.63 (-0.01), DCTH: 1.36 (+0.01)
Delcath Systems to conduct first-line treatment of patients with unresectable hepatocellular carcinoma in Tampa, Florida, USA
M2 - Tue Oct 07, 6:31AM CDT
Medical device company Delcath Systems (NasdaqCM
CTH) reported on Monday that it has begun its US clinical development programme for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer. DCTH: 1.36 (+0.01)
DELCATH COMMENCES U.S. PHASE 2 STUDY OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER
Thomson Reuters ONE - Thu Oct 02, 6:00AM CDT
Moffitt Cancer Center In Tampa, Florida Opens For Enrollment
DCTH: 1.36 (+0.01)
Jennifer Simpson, PH. D. Appointed Interim President and Interim-CEO of Delcath Systems; Roger G. Stoll, PH.D Named Executive Chairman
Thomson Reuters ONE - Mon Sep 15, 6:00AM CDT
- Company Enhances Clinical Development Program -
DCTH: 1.36 (+0.01)
5 Active Under-$10 Stocks to Buy Now
at The Street - Wed Aug 20, 5:30AM CDT
When a stock makes a large move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CRNT: 0.98 (+0.02), PXLW: 4.10 (+0.09), ESI: 10.18 (-0.01), ZHNE: 1.85 (+0.03), DCTH: 1.36 (+0.01)
Delcath Reports 2014 Second Quarter Results
PR Newswire - Wed Aug 06, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal second quarter ended June 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
DCTH: 1.36 (+0.01)
DELCATH TO REPORT SECOND QUARTER 2014 RESULTS ON AUGUST 6, 2014
Thomson Reuters ONE - Fri Aug 01, 5:30AM CDT
NEW YORK, NY - August 1, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, August 6, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter of 2014 ended June 30, 2014, and provide an update on recent corporate progress.
DCTH: 1.36 (+0.01)
